Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 + lymphoblastic leukaemias in vitro and in vivo

Josee Golay, N. Di Gaetano, D. Amico, E. Cittera, A. M. Barbui, R. Giavazzi, A. Biondi, A. Rambaldi, M. Introna

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid leukaemia. As approximately 18% of acute lymphoblastic leukaemias (ALL) are also CD33 positive, we have investigated the cytotoxic activity of GO on CD33+ ALL cells in vitro and in vivo. 10 ng/ml GO induced 30-95% inhibition of thymidine uptake and 30-70% cell death in four freshly isolated and one in vivo passaged CD33+ ALL-cell cultures. Furthermore, an in vivo model of a CD33+ ALL carrying the Philadelphia chromosome [t(9;22)] was established. 5 × 106 ALL-2 cells inoculated in the tail vein of severe combined immunodeficient mice engrafted into haematopoietic organs, reaching a mean of 70%, 61% and 69% human CD45 + cells in bone marrow, spleen and liver, respectively, at 35 d. To test the therapeutic activity of GO, 50 or 100 μg immunotoxin was inoculated i.p. on days 7, 11 and 15 following tumour-cell inoculation. GO treatment dramatically inhibited expansion of ALL-2 cells in all tested organs and increased survival of tumour-injected animals by 28-41 d, relative to controls. These data demonstrated that GO is active both in vitro and in vivo against CD33+ ALL cells.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalBritish Journal of Haematology
Volume128
Issue number3
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Antibodies, Monoclonal, Humanized
Immunotoxins
Tissue Survival
Philadelphia Chromosome
Chromosomes, Human, Pair 9
SCID Mice
In Vitro Techniques
gemtuzumab
Acute Myeloid Leukemia
Bone Marrow Cells
Thymidine
Tail
Anti-Idiotypic Antibodies
Veins
Neoplasms
Cell Death
Spleen
Cell Culture Techniques

Keywords

  • Acute lymphoblastic leukaemia
  • Animal model
  • CD33
  • Gemtuzumab ozogamicin
  • Immunotoxin

ASJC Scopus subject areas

  • Hematology

Cite this

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 + lymphoblastic leukaemias in vitro and in vivo. / Golay, Josee; Di Gaetano, N.; Amico, D.; Cittera, E.; Barbui, A. M.; Giavazzi, R.; Biondi, A.; Rambaldi, A.; Introna, M.

In: British Journal of Haematology, Vol. 128, No. 3, 02.2005, p. 310-317.

Research output: Contribution to journalArticle

Golay, Josee ; Di Gaetano, N. ; Amico, D. ; Cittera, E. ; Barbui, A. M. ; Giavazzi, R. ; Biondi, A. ; Rambaldi, A. ; Introna, M. / Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 + lymphoblastic leukaemias in vitro and in vivo. In: British Journal of Haematology. 2005 ; Vol. 128, No. 3. pp. 310-317.
@article{76278efbab54441881413684985c4ff0,
title = "Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 + lymphoblastic leukaemias in vitro and in vivo",
abstract = "Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid leukaemia. As approximately 18{\%} of acute lymphoblastic leukaemias (ALL) are also CD33 positive, we have investigated the cytotoxic activity of GO on CD33+ ALL cells in vitro and in vivo. 10 ng/ml GO induced 30-95{\%} inhibition of thymidine uptake and 30-70{\%} cell death in four freshly isolated and one in vivo passaged CD33+ ALL-cell cultures. Furthermore, an in vivo model of a CD33+ ALL carrying the Philadelphia chromosome [t(9;22)] was established. 5 × 106 ALL-2 cells inoculated in the tail vein of severe combined immunodeficient mice engrafted into haematopoietic organs, reaching a mean of 70{\%}, 61{\%} and 69{\%} human CD45 + cells in bone marrow, spleen and liver, respectively, at 35 d. To test the therapeutic activity of GO, 50 or 100 μg immunotoxin was inoculated i.p. on days 7, 11 and 15 following tumour-cell inoculation. GO treatment dramatically inhibited expansion of ALL-2 cells in all tested organs and increased survival of tumour-injected animals by 28-41 d, relative to controls. These data demonstrated that GO is active both in vitro and in vivo against CD33+ ALL cells.",
keywords = "Acute lymphoblastic leukaemia, Animal model, CD33, Gemtuzumab ozogamicin, Immunotoxin",
author = "Josee Golay and {Di Gaetano}, N. and D. Amico and E. Cittera and Barbui, {A. M.} and R. Giavazzi and A. Biondi and A. Rambaldi and M. Introna",
year = "2005",
month = "2",
doi = "10.1111/j.1365-2141.2004.05322.x",
language = "English",
volume = "128",
pages = "310--317",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 + lymphoblastic leukaemias in vitro and in vivo

AU - Golay, Josee

AU - Di Gaetano, N.

AU - Amico, D.

AU - Cittera, E.

AU - Barbui, A. M.

AU - Giavazzi, R.

AU - Biondi, A.

AU - Rambaldi, A.

AU - Introna, M.

PY - 2005/2

Y1 - 2005/2

N2 - Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid leukaemia. As approximately 18% of acute lymphoblastic leukaemias (ALL) are also CD33 positive, we have investigated the cytotoxic activity of GO on CD33+ ALL cells in vitro and in vivo. 10 ng/ml GO induced 30-95% inhibition of thymidine uptake and 30-70% cell death in four freshly isolated and one in vivo passaged CD33+ ALL-cell cultures. Furthermore, an in vivo model of a CD33+ ALL carrying the Philadelphia chromosome [t(9;22)] was established. 5 × 106 ALL-2 cells inoculated in the tail vein of severe combined immunodeficient mice engrafted into haematopoietic organs, reaching a mean of 70%, 61% and 69% human CD45 + cells in bone marrow, spleen and liver, respectively, at 35 d. To test the therapeutic activity of GO, 50 or 100 μg immunotoxin was inoculated i.p. on days 7, 11 and 15 following tumour-cell inoculation. GO treatment dramatically inhibited expansion of ALL-2 cells in all tested organs and increased survival of tumour-injected animals by 28-41 d, relative to controls. These data demonstrated that GO is active both in vitro and in vivo against CD33+ ALL cells.

AB - Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid leukaemia. As approximately 18% of acute lymphoblastic leukaemias (ALL) are also CD33 positive, we have investigated the cytotoxic activity of GO on CD33+ ALL cells in vitro and in vivo. 10 ng/ml GO induced 30-95% inhibition of thymidine uptake and 30-70% cell death in four freshly isolated and one in vivo passaged CD33+ ALL-cell cultures. Furthermore, an in vivo model of a CD33+ ALL carrying the Philadelphia chromosome [t(9;22)] was established. 5 × 106 ALL-2 cells inoculated in the tail vein of severe combined immunodeficient mice engrafted into haematopoietic organs, reaching a mean of 70%, 61% and 69% human CD45 + cells in bone marrow, spleen and liver, respectively, at 35 d. To test the therapeutic activity of GO, 50 or 100 μg immunotoxin was inoculated i.p. on days 7, 11 and 15 following tumour-cell inoculation. GO treatment dramatically inhibited expansion of ALL-2 cells in all tested organs and increased survival of tumour-injected animals by 28-41 d, relative to controls. These data demonstrated that GO is active both in vitro and in vivo against CD33+ ALL cells.

KW - Acute lymphoblastic leukaemia

KW - Animal model

KW - CD33

KW - Gemtuzumab ozogamicin

KW - Immunotoxin

UR - http://www.scopus.com/inward/record.url?scp=13444253828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444253828&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05322.x

DO - 10.1111/j.1365-2141.2004.05322.x

M3 - Article

C2 - 15667532

AN - SCOPUS:13444253828

VL - 128

SP - 310

EP - 317

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -